Loading...
No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers
Vorapaxar is a first‐in‐class antagonist of the protease‐activated receptor‐1, the primary thrombin receptor on human platelets, which mediates the downstream effects of thrombin in hemostasis and thrombosis. Prasugrel is a platelet inhibitor that acts as a P2Y12 receptor antagonist through an activ...
Na minha lista:
| Udgivet i: | Clin Pharmacol Drug Dev |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5811915/ https://ncbi.nlm.nih.gov/pubmed/28403576 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.354 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|